Brokerages Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Target Price at $43.17

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given an average rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $43.17.

Several analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, December 20th. TD Cowen began coverage on shares of Oruka Therapeutics in a report on Monday, September 16th. They issued a “buy” rating on the stock. Leerink Partners began coverage on shares of Oruka Therapeutics in a research note on Tuesday, September 17th. They set an “outperform” rating and a $44.00 target price for the company. Jefferies Financial Group assumed coverage on Oruka Therapeutics in a research note on Friday, September 13th. They issued a “buy” rating and a $40.00 price target on the stock. Finally, Leerink Partnrs raised Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock opened at $19.39 on Friday. Oruka Therapeutics has a 52-week low of $17.64 and a 52-week high of $53.88. The firm has a market cap of $678.63 million, a price-to-earnings ratio of -3.10 and a beta of 0.78. The business’s 50 day simple moving average is $23.29.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ORKA. Geode Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the third quarter valued at about $343,000. The Manufacturers Life Insurance Company purchased a new position in Oruka Therapeutics in the third quarter valued at about $1,037,000. Wellington Management Group LLP acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter valued at approximately $2,013,000. Janus Henderson Group PLC purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $5,840,000. Finally, Redmile Group LLC acquired a new stake in shares of Oruka Therapeutics in the 3rd quarter worth approximately $10,091,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.